TY - JOUR
T1 - Clinical trials of new drugs for Alzheimer disease
T2 - a 2020–2023 update
AU - Huang, Li Kai
AU - Kuan, Yi Chun
AU - Lin, Ho Wei
AU - Hu, Chaur Jong
N1 - Publisher Copyright:
© 2023, National Science Council of the Republic of China (Taiwan).
PY - 2023/12
Y1 - 2023/12
N2 - Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD.
AB - Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD.
KW - Alzheimer disease
KW - Anti-amyloid
KW - Anti-tau
KW - Clinical trials
KW - Cognitive enhancement
KW - Neuroinflammation
KW - Neuroprotection
UR - http://www.scopus.com/inward/record.url?scp=85173007402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173007402&partnerID=8YFLogxK
U2 - 10.1186/s12929-023-00976-6
DO - 10.1186/s12929-023-00976-6
M3 - Review article
C2 - 37784171
AN - SCOPUS:85173007402
SN - 1021-7770
VL - 30
JO - Journal of Biomedical Science
JF - Journal of Biomedical Science
IS - 1
M1 - 83
ER -